Navigation Links
TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter
Date:7/30/2009

PLEASANTON, Calif., July 30 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today CE mark approval of its second product, a novel coronary dilatation catheter, designed to improve the treatment of patients with complex coronary disease at or near side branches. The product will be marketed under the name Glider(TM).

The Glider(TM) is a first-in-class balloon dilatation catheter with a torquable shaft and novel tip design. These features permit the Glider(TM) to cross through tight lesions and stent struts. In addition, its unique balloon characteristics were designed to allow full dilatation of the side branch ostium and reduce the risk of dissections and side branch injuries.

"Conventional balloon catheters are not optimized to cross into side branches or to fully treat the ostium of the side branch. The unique characteristics of the Glider(TM) are designed to overcome these limitations," said Professor Carlo Di Mario from the Royal Brompton Hospital in London. "I am pleased to be working with TriReme as they develop products specifically tailored for the treatment of bifurcation disease."

"The Glider(TM) dilatation catheter follows the success of our Antares(R) stent system and is another important product in TriReme's toolbox enabling treatment of a broad range of bifurcation lesions," said Eitan Konstantino, Ph.D., President and Chief Executive Officer of TMI. "We are committed to developing a series of innovative products that will enable the best possible treatment for patients suffering from complex arterial disease."

About Bifurcation Disease

Approximately 20% of all atherosclerosis cases involve lesions at or near side branches in the coronary tree. Acute and long term outcomes in this subset of patients are worse than the outcomes of patients with simple lesions. Moreover, when percutaneously treating bifurcation lesions, interventional cardiologists use a variety of complex techniques that involve the modification and distortion of tubular stents designed for straight rather than branching arteries. To date in the US, no stents are approved for use in bifurcations. For these reasons, bifurcation lesions are common reasons for referral to coronary bypass surgery.

About TriReme Medical, Inc.

TriReme Medical, Inc. (TMI) is a privately held medical device company. TMI is based in California and dedicated to the development and manufacturing of novel stent technology and other devices for the treatment of atherosclerotic disease at or near bifurcations.

In April 2009, TriReme received CE mark for its Antares(R) SX stent system. Antares(R) is a main vessel stent that is designed to adapt to a broad variety of bifurcation lesions and coronary anatomies to produce predictable results during provisional stenting. To date, Antares(R) has been used in over 100 patients in Europe.

TMI can be contacted at +1 (925) 931-1300 or info@trirememedical.com.


'/>"/>
SOURCE TriReme Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: